EW · 10-Q · 2026Q2 · Full report

Acquisition / Partnership / Divestiture

Edwards Lifesciences Corp · 2026-08-04 · Importance 47 · Surprise 60 · In source text

Edwards acquired Autus Valve Technologies in February 2026 for total consideration of $128.9 million, including $35.1 million of cash consideration funded from existing cash. The transaction includes contingent consideration of up to $132.5 million tied to regulatory and sales milestones. In May 2026, amendments to agreements with a medical device company made Edwards the primary beneficiary of the Consolidated VIE, which was then consolidated. Edwards’ discontinued operations also reflect the September 2024 sale of Critical Care to Becton, Dickinson and Company and the December 2025 sale of a non-core product group.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
assetspositiverealized+0.9%In February 2026 Edwards completed the acquisition of Autus for total consideration of $128.9 million which included cash consideration of…
cashnegativerealized-0.3%In February 2026 Edwards completed the acquisition of Autus for total consideration of $128.9 million which included cash consideration of…
liabilitynegativecontingent-0.2%As of June 30, 2026 the potential future payments upon achievement of certain regulatory, performance, and sales milestones pursuant to…
liabilitynegativecontingentEdwards has purchased options to acquire and agreed to provide promissory notes to various entities which could result in additional cash…